Biomarker ID | 540 |
PMID | 20889560 |
Year | 2010 |
Biomarker | MMP-9 % |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Increased expression in Recurrence free survival |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR 0.88, (95% CI 0.78-0.99) |
Effect on Pathways | Pathway Includes:- Syndecan 1 pathway,Gastrin pathway,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,TWEAK signaling pathway, Endochondral ossification |
Experiment | Biochemical Recurrence Vs No Recurrence |
Type of Biomarker | Prognostic |
Cohort | 278 with prostate cancer were chosen. At the end time, 210 patients were alive, 228 patients had no event with regard to disease-specific mortality, and 87 patients were without biochemical recurrence were chosen. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.03 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | In multivariable analysis, none of these potential markers was found to be an independent prognostic factor of survival. % refers to percentage staining in immunohistochemistry |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | MMP9 |